<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: market new products", fill: "#b2ffff"},
{source: "2: market new products", target: "2: enhance existing products", fill: "#b2ffff"},
{source: "2: enhance existing products", target: "2: could lose market", fill: "#b2ffff"},
{source: "2: could lose market", target: "2: competitors", fill: "#b2ffff"},
{source: "2: competitors", target: "2: operations", fill: "#b2ffff"},
{source: "2: operations", target: "2: could suffer", fill: "#b2ffff"},
{source: "2: market new products", target: "5: technologically", fill: "#f0f"},
{source: "5: technologically", target: "5: significant", fill: "#f0f"},
{source: "5: significant", target: "5: development", fill: "#f0f"},
{source: "5: technologically", target: "10: Additionally ", fill: "#a52a2a"},
{source: "10: Additionally ", target: "10: manufacturing marketing", fill: "#a52a2a"},
{source: "10: manufacturing marketing", target: "10: difficulties", fill: "#a52a2a"},
{source: "10: difficulties", target: "10: could delay", fill: "#a52a2a"},
{source: "10: could delay", target: "10: development introduction", fill: "#a52a2a"},
{source: "10: development introduction", target: "10: new versions", fill: "#a52a2a"},
{source: "10: Additionally ", target: "20: competitors may", fill: "#ff2800"},
{source: "20: competitors may", target: "20: technologies", fill: "#ff2800"},
{source: "20: technologies", target: "20: products earlier", fill: "#ff2800"},
{source: "20: products earlier", target: "20: patent protection", fill: "#ff2800"},
{source: "20: patent protection", target: "20: regulatory clearance earlier", fill: "#ff2800"},
{source: "20: regulatory clearance earlier", target: "20: commercializing new products", fill: "#ff2800"},
{source: "20: commercializing new products", target: "20: rapidly than us", fill: "#ff2800"},
{source: "20: competitors may", target: "27: Accordingly ", fill: "#ff8c69"},
{source: "27: Accordingly ", target: "27: acquisitions may", fill: "#ff8c69"},
{source: "27: Accordingly ", target: "28: businesses", fill: "#fada5e"},
{source: "28: businesses", target: "28: technologies", fill: "#fada5e"},
{source: "28: technologies", target: "28: complementary", fill: "#fada5e"},
{source: "28: businesses", target: "29: such acquisitions would", fill: "#ff7518"},
{source: "29: such acquisitions would", target: "29: acquisitions", fill: "#ff7518"},
{source: "29: acquisitions", target: "29: accompanied by", fill: "#ff7518"},
{source: "29: accompanied by", target: "29: risks commonly encountered", fill: "#ff7518"},
{source: "29: risks commonly encountered", target: "29: potential disruption", fill: "#ff7518"},
{source: "29: potential disruption", target: "29: evaluate opportunities", fill: "#ff7518"},
{source: "29: evaluate opportunities", target: "29: opportunities", fill: "#ff7518"},
{source: "29: opportunities", target: "29: inability", fill: "#ff7518"},
{source: "29: inability", target: "29: management", fill: "#ff7518"},
{source: "29: management", target: "29: position by incorporating", fill: "#ff7518"},
{source: "29: position by incorporating", target: "29: technology", fill: "#ff7518"},
{source: "29: technology", target: "29: existing offerings", fill: "#ff7518"},
{source: "29: existing offerings", target: "29: difficulty", fill: "#ff7518"},
{source: "29: difficulty", target: "29: uniform standards controls procedures", fill: "#ff7518"},
{source: "29: uniform standards controls procedures", target: "29: assimilating", fill: "#ff7518"},
{source: "29: assimilating", target: "29: operations", fill: "#ff7518"},
{source: "29: operations", target: "29: businesses", fill: "#ff7518"},
{source: "29: businesses", target: "29: potential loss", fill: "#ff7518"},
{source: "29: potential loss", target: "29: key employees", fill: "#ff7518"},
{source: "29: key employees", target: "29: impairment", fill: "#ff7518"},
{source: "29: impairment", target: "29: relationships with employees", fill: "#ff7518"},
{source: "29: relationships with employees", target: "29: customers as", fill: "#ff7518"},
{source: "29: customers as", target: "29: uncertainty as", fill: "#ff7518"},
{source: "29: uncertainty as", target: "29: longterm success", fill: "#ff7518"},
{source: "29: such acquisitions would", target: "33: could incur", fill: "#3c1414"},
{source: "33: could incur", target: "33: significant amounts", fill: "#3c1414"},
{source: "33: significant amounts", target: "33: indebtedness", fill: "#3c1414"},
{source: "33: indebtedness", target: "33: connection with acquisitions", fill: "#3c1414"},
{source: "33: could incur", target: "35: adequately protect", fill: "#cfb53b"},
{source: "35: adequately protect", target: "35: intellectual property rights", fill: "#cfb53b"},
{source: "35: adequately protect", target: "38: patent trade secret copyright knowhow", fill: "#ffdab9"},
{source: "38: patent trade secret copyright knowhow", target: "38: trademark laws as well as", fill: "#ffdab9"},
{source: "38: trademark laws as well as", target: "38: license agreements", fill: "#ffdab9"},
{source: "38: license agreements", target: "38: contractual provisions", fill: "#ffdab9"},
{source: "38: contractual provisions", target: "38: intellectual", fill: "#ffdab9"},
{source: "38: intellectual", target: "38: property rights", fill: "#ffdab9"},
{source: "38: patent trade secret copyright knowhow", target: "START_HERE", fill: "#ffdab9"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dysphagia">Dysphagia</a></td>
      <td>Dysphoria (from Ancient Greek  δύσφορος (dúsphoros) 'grievous'; from  δυσ- (dus-) 'bad, difficult', and  φέρω (phérō) 'to bear') is a profound state of unease or dissatisfaction. It is the opposite of euphoria.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patent_claim">Patent claim</a></td>
      <td>In a patent or patent application, the claims define, in technical terms, the extent, i.e. the scope, of the protection conferred by a patent, or the protection sought in a patent application.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_mergers_and_acquisitions_by_Meta_Platforms">List of mergers and acquisitions by Meta Platforms</a></td>
      <td>Meta Platforms (formerly Facebook, Inc.) is a technology company that has acquired 91 other companies, including WhatsApp. The WhatsApp acquisition closed at a steep $16 billion; more than $40 per user of the platform.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bolt-on_acquisition">Bolt-on acquisition</a></td>
      <td>Bolt-on acquisition refers to the acquisition of smaller companies, usually in the same line of business, that presents strategic value. This is in contrast to primary acquisitions of other companies which are generally in different industries, require larger investments, or are of similar size to the acquiring company.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Library_acquisitions">Library acquisitions</a></td>
      <td>Library acquisitions is the department of a library responsible for the selection and purchase of materials or resources. The department may select vendors, negotiate consortium pricing, arrange for standing orders, and select individual titles or resources.Libraries, both physical and digital, usually have four common broad goals that help dictate these responsibilities.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_acquisitions_by_Oracle">List of acquisitions by Oracle</a></td>
      <td>This is a listing of Oracle Corporation's corporate acquisitions, including acquisitions of both companies and individual products.\nOracle's version does not include value of the acquisition.See also Category:Sun Microsystems acquisitions (Sun was acquired by Oracle).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business-to-business">Business-to-business</a></td>
      <td>Business-to-business (B2B or, in some countries, BtoB) is a situation where one business makes a commercial transaction with another. This typically occurs when:\n\nA business is sourcing materials for their production process for output   (e.g., a food manufacturer purchasing salt), i.e.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_Is_Business">Business Is Business</a></td>
      <td>Business-to-business (B2B or, in some countries, BtoB) is a situation where one business makes a commercial transaction with another. This typically occurs when:\n\nA business is sourcing materials for their production process for output   (e.g., a food manufacturer purchasing salt), i.e.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Small_business">Small business</a></td>
      <td>Small businesses are  corporations, partnerships, or sole proprietorships which have fewer employees and/or less annual revenue than a regular-sized business or corporation. Businesses are defined as "small" in terms of being able to apply for government support and qualify for preferential tax policy varies depending on the country and industry.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_is_business">Business is business</a></td>
      <td>Business-to-business (B2B or, in some countries, BtoB) is a situation where one business makes a commercial transaction with another. This typically occurs when:\n\nA business is sourcing materials for their production process for output   (e.g., a food manufacturer purchasing salt), i.e.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_Proposal">Business Proposal</a></td>
      <td>Business Proposal (Korean: 사내 맞선; Hanja: 社內맞선; RR: Sanae Matseon; lit. The Office Blind Date) is a South Korean romantic comedy television series based on the webtoon of the same title written by HaeHwa and illustrated by Narak.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Knowledge_acquisition">Knowledge acquisition</a></td>
      <td>Knowledge acquisition is the process used to define the rules and ontologies required for a knowledge-based system. The phrase was first used in conjunction with expert systems to describe the initial tasks associated with developing an expert system, namely finding and interviewing domain experts and capturing their knowledge via rules, objects, and frame-based ontologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ben_Ashkenazy">Ben Ashkenazy</a></td>
      <td>Ben Ashkenazy (born 1968/69) is an American billionaire real estate developer. He is the founder, CEO, and majority owner of Ashkenazy Acquisition Corporation, which has a $12 billion property portfolio.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Action_film">Action film</a></td>
      <td>Action film is a film genre in which the protagonist is thrust into a series of events that typically involve violence and physical feats.\nThe genre tends to feature a mostly resourceful hero struggling against incredible odds, which include life-threatening situations, a dangerous villain, or a pursuit which usually concludes in victory for the hero.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_infringement">Intellectual property infringement</a></td>
      <td>An intellectual property (IP) infringement is the infringement or violation of an intellectual property right. There are several types of intellectual property rights, such as copyrights, patents, trademarks, industrial designs, and trade secrets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Exhaustion_of_intellectual_property_rights">Exhaustion of intellectual property rights</a></td>
      <td>The exhaustion of intellectual property rights constitutes one of the limits of intellectual property (IP) rights. Once a given product has been sold under the authorization of the IP owner, the reselling, rental, lending and other third party commercial uses of IP-protected goods in domestic and international markets is governed by the principle.After a product covered by an IP right, such as by a patent right, has been sold by the IP right owner or by others with the consent of the owner, the IP right is said to be exhausted.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_in_China">Intellectual property in China</a></td>
      <td>Intellectual property rights (IPRs) have been acknowledged and protected in China since the 1980s. China has acceded to the major international conventions on protection of rights to intellectual property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Libertarian_perspectives_on_intellectual_property">Libertarian perspectives on intellectual property</a></td>
      <td>Libertarians have differing opinions on the validity of intellectual property.\n\n\n== Political parties ==\nThe Libertarian Party of Canada takes "a moderate approach to patents and copyrights", calling for "a careful review of existing and proposed legislation".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Plant_breeders'_rights">Plant breeders' rights</a></td>
      <td>Plant breeders' rights (PBR), also known as plant variety rights (PVR), are rights granted to the breeder of a new variety of plant that give the breeder exclusive control over the propagating material (including seed, cuttings, divisions, tissue culture) and harvested material (cut flowers, fruit, foliage) of a new variety for a number of years.\nWith these rights, the breeder can choose to become the exclusive marketer of the variety, or to license the variety to others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trademark_infringement">Trademark infringement</a></td>
      <td>Trademark infringement is a violation of the exclusive rights attached to a trademark without the authorization of the trademark owner or any licensees (provided that such authorization was within the scope of the licence). Infringement may occur when one party, the "infringer", uses a trademark which is identical or confusingly similar to a trademark owned by another party, in relation to products or services which are identical or similar to the products or services which the registration covers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Women's_property_rights">Women's property rights</a></td>
      <td>Women's property rights are property and inheritance rights enjoyed by women as a category within a society.\nProperty rights are claims to property that are legally and socially recognized and enforceable by external legitimized authority.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Real_property">Real property</a></td>
      <td>In English common law, real property, real estate, immovable property or, solely in the US, realty, is land which is the property of some person and all structures (also called improvements or fixtures) integrated with or affixed to the land, including crops, buildings, machinery, wells, dams, ponds, mines, canals, and roads, among other things. The term is historic, arising from the now-discontinued form of action, which distinguished between real property disputes and personal property disputes.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>These factors include the following:         If we fail to develop or <font color="blue">market new products</font> and <font color="blue">enhance existing products</font>,     we <font color="blue">could lose market</font> share to our <font color="blue"><font color="blue">competitor</font>s</font> and our results of <font color="blue">operations</font>     <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>The  market  for  interventional  devices  is  <font color="blue">characterized</font>  by rapid     <font color="blue">technological</font> change, new product introductions, <font color="blue">technological</font> improvements,     changes in <font color="blue">physician requirements</font> and <font color="blue">evolving industry standards</font></td>
    </tr>
    <tr>
      <td>To be     successful, we <font color="blue">must continue</font> to develop and <font color="blue">commercialize new products</font> and     to  enhance  versions  of  our  existing  products</td>
    </tr>
    <tr>
      <td>Our  products are     <font color="blue">technological</font>ly  complex  and  require  <font color="blue">significant</font>  planning, design,     <font color="blue">development</font> and testing before they may be marketed</td>
    </tr>
    <tr>
      <td>This <font color="blue">process generally</font>     takes at least 12 to 18 months from initial concept and may take up to     <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>In addition, product life cycles are <font color="blue">relatively</font> short because     medical device <font color="blue">manufacturers continually</font> develop smaller, more <font color="blue">effective</font> and     <font color="blue">less expensive versions</font> of <font color="blue">existing devices</font> in response to <font color="blue">physician demand</font></td>
    </tr>
    <tr>
      <td>Our success in developing and <font color="blue">commercializing new</font> and <font color="blue">enhanced versions</font> of     our products is <font color="blue">affected by</font> our ability to:           •   timely and <font color="blue">accurately</font> identify <font color="blue">new market trends</font>;           •   <font color="blue">accurately</font> assess customer needs;           •   minimize the time and costs required to obtain <font color="blue">regulatory clearance</font> or     approval;           •   <font color="blue">adopt competitive pricing</font>;           •   <font color="blue">timely manufacture</font> and deliver products;           •   <font color="blue">accurately</font> predict and <font color="blue">control costs associated with</font> the <font color="blue">development</font>,     <font color="blue">manufacturing</font> and support of our products; and           •   anticipate and compete <font color="blue">effective</font>ly with our <font color="blue"><font color="blue">competitor</font>s</font>’ efforts</td>
    </tr>
    <tr>
      <td>Market  <font color="blue">acceptance</font>  of  our products depends in part on our ability to     <font color="blue">demonstrate</font> that our products are cost-<font color="blue">effective</font> and easier to use, as well     as offer <font color="blue">technological</font> advantages</td>
    </tr>
    <tr>
      <td>Additionally, we may experience design,     <font color="blue">manufacturing</font>, marketing or other <font color="blue">difficulties</font> that <font color="blue">could delay</font> or prevent     our <font color="blue">development</font>, introduction or marketing of <font color="blue">new versions</font> of our products</td>
    </tr>
    <tr>
      <td>As a result of such <font color="blue">difficulties</font> and delays, our <font color="blue">development</font> expenses may     increase and, as a consequence, our results of <font color="blue">operations</font> <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>may decrease our market share and cause our revenues to decline</td>
    </tr>
    <tr>
      <td>The markets for <font color="blue">interventional devices</font> are <font color="blue">highly competitive</font>, and we expect     <font color="blue">competition</font>  to  continue  to intensify</td>
    </tr>
    <tr>
      <td>We may not be able to compete     <font color="blue">effective</font>ly, and we <font color="blue">may lose market</font> share to our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>The principal     <font color="blue"><font color="blue">competitor</font>s</font>  in the markets for our <font color="blue">products currently</font> include: Boston     Scientific Corporation; Cook, Incorporated; Cordis Corporation, a subsidiary     of Johnson &amp; Johnson, Inc</td>
    </tr>
    <tr>
      <td>; Medical Components,     Inc,  or  Medcomp;  and  VNUS  Medical Technologies, Inc</td>
    </tr>
    <tr>
      <td>Many of our     <font color="blue"><font color="blue">competitor</font>s</font> have <font color="blue">substantially</font> greater:           •   financial and other resources;           •   variety of products;           •   <font color="blue">technical capabilities</font>;           •   ability to develop and <font color="blue">introduce new products</font>;           •   <font color="blue">patent portfolios</font> that <font color="blue">may present</font> an obstacle to our conduct of     business;           •   <font color="blue">name recognition</font>; and           •   <font color="blue">distribution networks</font> and in-house sales forces</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________    [38]Table of Contents       Our <font color="blue"><font color="blue">competitor</font>s</font> may succeed in developing <font color="blue">technologies</font> and <font color="blue">products earlier</font>,     in  obtaining <font color="blue">patent protection</font> or <font color="blue">regulatory clearance</font> earlier, or in     <font color="blue">commercializing new</font> products or <font color="blue">technologies</font> more <font color="blue">rapidly than us</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue"><font color="blue">competitor</font>s</font> may also develop products and <font color="blue">technologies</font> that are superior to     those we are developing or that <font color="blue">otherwise could</font> render our <font color="blue">products obsolete</font>     or <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>In addition, we may face <font color="blue">competition</font> from providers of     other medical therapies, such as pharmaceutical companies, that may offer     non-surgical therapies for <font color="blue">conditions</font> that are currently or in the future     may be <font color="blue">treated using</font> our products</td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">generally sold at higher</font>     <font color="blue">prices than</font> those of our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>However, in the <font color="blue">current environment</font> of     managed care, which is <font color="blue">characterized</font> by economically motivated buyers,     <font color="blue">consolidation</font>  among  healthcare  providers, increased <font color="blue">competition</font> and     <font color="blue">declining reimbursement rates</font>, we are <font color="blue">increasingly</font> being required to compete     on the basis of price</td>
    </tr>
    <tr>
      <td>If we are not able to compete <font color="blue">effective</font>ly, our market     share and <font color="blue">revenues may decline</font></td>
    </tr>
    <tr>
      <td>We  may  be  exposed  to <font color="blue">risks associated with <font color="blue">acquisitions</font></font>, including     <font color="blue">integration risks</font> and <font color="blue">risks associated with methods</font> of financing and the     impact of <font color="blue">accounting treatment</font></td>
    </tr>
    <tr>
      <td>Accordingly, completed <font color="blue"><font color="blue">acquisitions</font> may</font> not     enhance our business</td>
    </tr>
    <tr>
      <td>Part of our growth strategy is to acquire <font color="blue">businesses</font> and <font color="blue">technologies</font> that     are <font color="blue">complementary</font> to ours</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such <font color="blue">acquisitions</font> would</font> be <font color="blue">accompanied by</font> the     <font color="blue">risks commonly encountered</font> in <font color="blue">acquisitions</font>, including the:           •   <font color="blue">potential disruption</font> of our business while we <font color="blue">evaluate <font color="blue">opportunities</font></font>,     complete <font color="blue">acquisitions</font> and develop and implement new business strategies to     take advantage of these <font color="blue">opportunities</font>;           •   <font color="blue">inability</font> of our <font color="blue">management</font> to maximize our financial and strategic     <font color="blue">position by incorporating</font> an acquired <font color="blue">technology</font> or business into our     <font color="blue">existing offerings</font>;           •   <font color="blue">difficulty</font> of maintaining uniform standards, controls, procedures and     policies;           •   <font color="blue">difficulty</font> of <font color="blue">assimilating</font> the <font color="blue">operations</font> and personnel of acquired     <font color="blue">businesses</font>;           •   <font color="blue">potential loss</font> of <font color="blue">key employees</font> of acquired <font color="blue">businesses</font>, and the     <font color="blue">impairment</font> of <font color="blue">relationships with employees</font> and <font color="blue">customers as</font> a result of     changes in <font color="blue">management</font>; and           •   <font color="blue">uncertainty as</font> to the long-term success of any <font color="blue">acquisitions</font> we may     make</td>
    </tr>
    <tr>
      <td>We  cannot  assure you that any completed <font color="blue">acquisition will enhance</font> our     business</td>
    </tr>
    <tr>
      <td>If we <font color="blue">proceed with one</font> or more <font color="blue">significant</font> <font color="blue">acquisitions</font> in which     the <font color="blue">consideration consists</font> of cash, a substantial portion of our available     cash, could be used to consummate the <font color="blue">acquisitions</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">consummate one</font> or     more <font color="blue">acquisitions</font> in which the <font color="blue">consideration consists</font> of <font color="blue">capital stock</font>, our     stockholders <font color="blue">could suffer</font> <font color="blue">significant</font> dilution of their interest in us</td>
    </tr>
    <tr>
      <td>In     addition, we <font color="blue">could incur</font> or assume <font color="blue">significant</font> amounts of <font color="blue">indebtedness</font> in     connection with <font color="blue">acquisitions</font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue">acquisitions</font> <font color="blue">could also</font> result in     <font color="blue">significant</font> goodwill and/or amortization charges for acquired <font color="blue">businesses</font> or     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">adequately protect</font> our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>, our     business may suffer</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on obtaining, maintaining and enforcing our     patents, trademarks and other <font color="blue">proprietary rights</font>, and our ability to avoid     infringing the <font color="blue">proprietary rights</font> of others</td>
    </tr>
    <tr>
      <td>We take <font color="blue">precautionary</font> steps to     protect our <font color="blue">technological</font> advantages and <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>We rely upon     patent, trade secret, copyright, know-how and trademark laws, as well as     <font color="blue">license <font color="blue">agreements</font></font> and <font color="blue">contractual provisions</font>, to establish our <font color="blue">intellectual</font>     <font color="blue">property rights</font> and protect our products</td>
    </tr>
    <tr>
      <td>However, these <font color="blue">measures may</font> not     <font color="blue">adequately protect</font> our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>Our  patents  may  not  provide commercially meaningful protection, as     <font color="blue"><font color="blue">competitor</font>s</font> may be able to <font color="blue">design around</font> our patents to produce <font color="blue">alternative</font>,     non-infringing designs</td>
    </tr>
    <tr>
      <td>Additionally, we may not be able to <font color="blue">effective</font>ly     protect our rights in unpatented <font color="blue">technology</font>, trade secrets and <font color="blue">confidential</font>     information</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  require our new employees, consultants and     <font color="blue">corporate partners</font> to execute <font color="blue">confidential</font>ity <font color="blue">agreements</font>, these <font color="blue">agreements</font>     may not provide <font color="blue">effective</font> protection of our information or, in the event of     <font color="blue">unauthorized use</font> or disclosure, may not <font color="blue">provide adequate remedies</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________    [39]Table of Contents       If  third  parties claim that our <font color="blue">products infringe</font> their <font color="blue">intellectual</font>     <font color="blue">property rights</font>, we may be forced to expend <font color="blue">significant</font> financial resources     and  <font color="blue">management</font> time <font color="blue">defending against such actions</font> and our results of     <font color="blue">operations</font> <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> claim that our <font color="blue">products infringe</font> their patents and other     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td><font color="blue">Identifying </font>third-party patent rights can be     <font color="blue">particularly difficult</font> because, in general, patent applications can be     maintained in secrecy for at least 18 months after their <font color="blue">earliest priority</font>     date</td>
    </tr>
    <tr>
      <td>Some companies in the medical device industry have used <font color="blue">intellectual</font>     <font color="blue">property <font color="blue">infringement</font> litigation</font> to gain a <font color="blue">competitive advantage</font></td>
    </tr>
    <tr>
      <td>If a     <font color="blue">competitor</font> were to challenge our patents, licenses or other <font color="blue">intellectual</font>     <font color="blue">property rights</font>, or assert that our <font color="blue">products infringe</font> its patent or other     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>, we <font color="blue">could incur</font> substantial <font color="blue">litigation costs</font>,     be forced to make expensive changes to our product design, license rights in     order to continue <font color="blue">manufacturing</font> and selling our products, or pay substantial     damages</td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">infringement</font> claims, <font color="blue">regardless</font> of their outcome, would     not <font color="blue">only consume</font> our <font color="blue">financial resources but also divert</font> our <font color="blue">management</font>’s     time and effort</td>
    </tr>
    <tr>
      <td>Such claims <font color="blue">could also</font> cause our customers or potential     customers to purchase <font color="blue"><font color="blue">competitor</font>s</font>’ products or defer or limit their purchase     or use of our <font color="blue">affected products until resolution</font> of the claim</td>
    </tr>
    <tr>
      <td>In  January  2004, Diomed filed an <font color="blue"><font color="blue">action against</font> us</font> alleging that our     VenaCure products for the treatment of <font color="blue">varicose veins infringe</font> a patent held     by Diomed for a <font color="blue">laser system</font> that <font color="blue">competes with</font> our VenaCure products</td>
    </tr>
    <tr>
      <td>Diomed’s <font color="blue">complaint seeks injunctive relief</font> and <font color="blue">compensatory</font> and treble     damages</td>
    </tr>
    <tr>
      <td>In October 2005, VNUS Medical Technologies filed an <font color="blue">action against</font>     us, Diomed and another <font color="blue">defendant</font> alleging, among other things, that the     manufacture, use and sale of our VenaCure <font color="blue">products infringe</font> several patents     held by VNUS and seeking injunctive relief and <font color="blue">compensatory</font> and treble     damages</td>
    </tr>
    <tr>
      <td>For fiscal 2006, sales of our VenaCure <font color="blue">products accounted</font> for     approximately 15prca of our <font color="blue">total sales</font></td>
    </tr>
    <tr>
      <td>If Diomed or VNUS Medical Technologies     is successful in its <font color="blue"><font color="blue">action against</font> us</font>, our results of <font color="blue">operations</font> could</td>
    </tr>
  </tbody>
</table>